.15e4dc1dd95d816d.png)
Discover our extensive range of high-quality vaccines, biologics, and diagnostic solutions designed to make healthcare accessible, reliable, and affordable worldwide.
| Label Composition | Each single dose of 0.5 mL contains: • Tetanus Toxoid — 7.5 Lf • Diphtheria Toxoid — 2.0 Lf • Bordetella pertussis antigens: • Recombinant Pertussis Toxin (rPT) — 2 µg • Filamentous Haemagglutinin (FHA) — 5 µg |
| Pack | 0.5 mL Prefilled Syringe |
| Therapeutic Use | Active booster immunization against diphtheria, tetanus and pertussis in individuals aged 4 to 65 years. |
| Label Composition | Each single dose of 0.5 mL contains: • Live Attenuated Varicella-Herpes Zoster Virus (Oka strain) — 3.3 to 4.5 lg PFU/0.5 mL per dose • Produced in human diploid (SV-1) cells • International standard virus strain purchased from ATCC • Virus titer tested using an in-house reference |
| Pack | Vial and WFI |
| Therapeutic Use | Active immunization against infection caused by varicella in individuals aged 1 year (12 months) to 12 years. |
| Label Composition | Each single dose of 0.5 mL contains: • Inactivated HAV antigen (TZ84 strain)¹ — 250 U • Aluminium, as Aluminium Hydroxide — 0.175 to 0.31 mg • Disodium Hydrogen Phosphate — q.s. • Sodium Chloride — 4.5 mg • Sodium Dihydrogen Phosphate — q.s. • Water for Injection — q.s. to 0.5 mL • ¹ Produced in Human Diploid Cells |
| Pack | Vial / Prefilled Syringe |
| Therapeutic Use | Active immunization against infection caused by Hepatitis A virus. |
| Label Composition | Each single dose of 0.5 mL contains: • Each 0.5 mL dose contains 15 µg haemagglutinin (HA) of each influenza virus strain selected in accordance with the annual recommendations of the World Health Organization (WHO) for the applicable Northern or Southern Hemisphere influenza season. |
| Pack | Prefilled Syringe |
| Therapeutic Use | Active immunization of adults aged 18 years and older for prevention of influenza disease. |
Built to support availability of essential vaccines across priority markets.
Focused on regulated, market-authorized vaccine candidates.
Designed for institutional, commercial and public health collaborations.
For any questions or to report an Adverse Event, please contact our AE Reporting team:
Your privacy is important to us.
All AE reports shall be handled with strict confidentiality.
Personal information is protected and used solely for safety monitoring purposes.
Connect with TechInvention to explore product availability, licensing partnerships and access opportunities for market-authorized vaccines.